At 6.3x trailing P/S after a ~57% slide from its IPO high, with FY2025 revenue up 97%, positive free cash flow, and a molecular database rivals cannot replicate — WATCHLIST while the 2026 growth-deceleration guidance plays through; the 10-year bull case already clears the 10x aim at today's price, and a dip toward ~5x P/S (~$14–15, the 52-week low) would flip this to BUY.